Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Ananda Pharma Plc Share Issue/Capital Change 2021

Jul 16, 2021

10286_sha_2021-07-16_116a01ad-f62d-4835-a4f7-472ed043b4af.html

Share Issue/Capital Change

Open in viewer

Opens in your device viewer

{# SEO P0-1: filing HTML is rendered server-side so Googlebot sees the full text without executing JS or following an iframe to a Disallow'd CDN path. The content has already been sanitized through filings.seo.sanitize_filing_html. #}

National Storage Mechanism | Additional information

Ananda Developments Plc - Issue of Equity

PR Newswire

London, July 16

16 July 2021

ANANDA DEVELOPMENTS PLC

(“Ananda” or the “Company”)

ISSUE OF EQUITY

Ananda announces that 96,890 ordinary shares of 0.2p each in the Company (“Ordinary Shares”) have been issued following the exercise of warrants at 0.45p per share. The proceeds receivable by the Company will be used for general working capital purposes.

Application will be made for the new Ordinary Shares to be admitted to trading on the Access segment of the AQSE Growth Market and admission is expected to become effective on Thursday, 22 July 2021.

Following this issue, the Company has 794,501,216 Ordinary Shares in issue, each share carrying the right to one vote.

This figure of 794,501,216 Ordinary Shares may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.

-Ends-

The Directors of the Company accept responsibility for the contents of this announcement.

ANANDA DEVELOPMENTS PLC

Chief Executive Officer

Melissa Sturgess



Investor Relations

Jeremy Sturgess-Smith
+44 (0)7717 573 235

[email protected]
PETERHOUSE CAPITAL LIMITED

Corporate Finance

Mark Anwyl

Allie Feuerlein



Corporate Broking

Lucy Williams

Duncan Vasey
+44 (0)20 7469 0930

Market Abuse Regulation (MAR) Disclosure

The information contained within this announcement is deemed by the Company to constitute inside information. Upon the publication of this announcement via a Regulatory Information Service, this inside information is now considered to be in the public domain.